Market Research Report
HER2 Positive Gastric Cancer - Pipeline Insight, 2021
|HER2 Positive Gastric Cancer - Pipeline Insight, 2021|
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
DelveInsight's, "HER2 Positive Gastric Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in HER2 Positive Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric and gastroesophageal junction cancer. Many studies have evaluated the relationship between HER2 status and prognosis in patients with gastric cancer. Unlike in breast cancer, the studies in gastric cancer to date have yielded inconsistent findings regarding the prognostic relevance of HER2. Some showed that HER2 positivity was associated with a significantly worse prognosis, whereas others found no association between HER2 status and prognosis, or that median overall survival was longer in HER2-positive than in HER2-negative patients. Therefore, the relationship between HER2 status and prognosis of gastric cancer patients remains controversial.
"HER2 Positive Gastric Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2 Positive Gastric Cancer pipeline landscape is provided which includes the disease overview and HER2 Positive Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2 Positive Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Positive Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence HER2 Positive Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HER2 Positive Gastric Cancer.
This segment of the HER2 Positive Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tecentriq® contains a monoclonal antibody, which binds with the PD-L1 protein expressed on tumour cells and tumour-infiltrating immune cells. It restrains interactions with both PD-1 and B7.1 receptors and enables the activation of T cells.
GQ1001 is an antibody drug conjugate (ADC) that is currently in global multi-center clinical trial development for treatment of HER2+ solid tumor. GQ1001 was synthesized by site-specific conjugation of toxin DM1 to trastuzumab, based on GQ exclusive ligase-dependent conjugation and a patented ring-opened linker technologies. Using GQ technologies, the linker stability and homogeneity of GQ1001 were significantly improved, expanding the therapeutic window of GQ1001.
This segment of the report provides insights about the different HER2 Positive Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the therapies for HER2 Positive Gastric Cancer. The companies which have their HER2 Positive Gastric Cancer drug candidates in the most advanced stage, i.e. phase I include, GeneQuantum Healthcare.
DelveInsight's report covers around 15+ products under different phases of clinical development like:
HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2 Positive Gastric Cancer therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2 Positive Gastric Cancer drugs.